



Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

August 31, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 31, 2023-- [Kezar Life Sciences, Inc.](#) (Nasdaq: [KZR](#)), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will participate in three upcoming investor conferences taking place in September:

- **Event:** 2023 Wells Fargo Healthcare Conference
Location: Boston, MA
Date/Time: Thursday, September 7, 2023, at 12:45 pm ET
Presenter: Noreen R. Henig, M.D., Chief Medical Officer
Format: Fireside Chat
- **Event:** Morgan Stanley 21st Annual Global Healthcare Conference
Location: New York, NY
Date/Time: Tuesday, September 12, 2023, at 10:50 am ET
Presenter: John Fowler, Co-Founder and Chief Executive Officer
Format: Fireside Chat
- **Event:** H.C. Wainwright 25th Annual Global Investment Conference
Location: New York, NY
Date/Time: Wednesday, September 13, 2023, at 12:30 pm ET
Presenter: John Fowler, Co-Founder and Chief Executive Officer
Format: Podium Presentation

Webcasts from the presentations will be available on the "Events & Presentations" section of the Company's website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor that has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company's platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com and follow us on [LinkedIn](#), [Facebook](#), [Twitter](#) and [Instagram](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20230831496066/en/>

Investor Contact:

Gitanjali Jain
Vice President, Investor Relations and External Affairs
gjain@kezarbio.com

Media Contact:

Will Zasadny
Evoke Canale
will.zasadny@evokegroup.com

Source: Kezar Life Sciences, Inc.